NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE: ENZ), a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services, announced that data from a Phase II clinical trial was presented today at Digestive Disease Week, the largest international gathering of academic researchers and practicing physicians in gastrointestinal medicine, held this year in Chicago. The data indicate that Alequel™, the Company’s investigational individualized oral immune regulation preparation, may be effective for the treatment of moderate-to-severe Crohn’s disease.
